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Creation and Assessment of a Clinical Predictive 
Calculator and Mortality Associated With Candida krusei 
Bloodstream Infections
Ryan Kronen,1 Kevin Hsueh,2 Charlotte Lin,3 William G. Powderly,2 and Andrej Spec2
1Washington University School of Medicine, St Louis, Missouri; and 2Division of Infectious Diseases and 3Department of Medicine, Washington University School of Medicine, St Louis, Missouri
Background. Candida krusei bloodstream infection (CK BSI) is associated with high mortality, but whether this is due to under-
lying comorbidities in affected patients or the organism itself is unknown. Identifying patient characteristics that are associated with 
CK BSI is crucial for clinical decision-making and prognosis.
Methods. We conducted a retrospective analysis of hospitalized patients with Candida BSI at our institution between 2002 and 
2015. Data were collected on demographics, comorbidities, medications, procedures, central lines, vital signs, and laboratory values. 
Multivariable logistic and Cox regression were used to identify risk factors associated with CK and mortality, respectively.
Results. We identified 1873 individual patients who developed Candida BSI within the study period, 59 of whom had CK BSI. 
CK BSI was predicted by hematologic malignancy, gastric malignancy, neutropenia, and the use of prophylactic azole antifun-
gals, monoclonal antibodies, and β-lactam/β-lactamase inhibitor combinations. The C-statistic was 0.86 (95% confidence interval, 
0.81–0.91). The crude mortality rates were 64.4% for CK BSI and 41.4% for non-CK BSI. Although CK was associated with higher 
mortality in univariable Cox regression, this relationship was no longer significant with the addition of the following confounders: 
lymphoma, neutropenia, glucocorticoid use, chronic liver disease, and elevated creatinine.
Conclusions. Six patient comorbidities predicted the development of CK BSI with high accuracy. Although patients with CK 
BSI have higher crude mortality rates than patients with non-CK BSI, this difference is not significant when accounting for other 
patient characteristics.
Keywords. Candida krusei; candidemia; clinical predictive model; mortality; risk factors. 
Candida bloodstream infection (BSI) is the most common form 
of invasive candidiasis, the fourth leading cause of bloodstream 
infections in the United States, and the most common nosoco-
mial BSI with non-albicans BSI, constituting a larger propor-
tion of total infections in recent decades [1–3]. These species 
include C. glabrata, C.  tropicalis, C. parapsilosis, and C. krusei 
(CK). Together with C. albicans, they make up the vast majority 
of Candida BSI. Although relatively rare, CK BSI is known to 
affect immunocompromised patients and is associated with the 
highest mortality among the Candida species [4–6].
The unique factors contributing to the development of infec-
tion by this organism and its clinical consequences are poorly 
characterized. Some predisposing factors, such as hematologic 
malignancy, are established in the literature as risk factors for 
CK BSI [7, 8]. Other risk factors including antibiotic exposure, 
surgery, and age exhibit a high level of heterogeneity across stud-
ies [9–12]. Most of these studies are limited by CK sample sizes 
of less than 35, and they often analyze for non-albicans Candida, 
which is influenced by C. glabrata, which has different risk fac-
tors [7–11]. In addition, few studies have addressed the question 
of whether the organism is directly responsible for the observed 
increase in mortality, or whether this association is confounded 
by other patient characteristics. While several authors have 
examined risk factors for mortality within Candida BSI cohorts 
[13], the multivariable survival models needed to definitively 
answer this question are lacking. Given the poor outcomes asso-
ciated with CK BSI, accurately identifying patients at risk for this 
infection could be of benefit to clinicians.
We performed a retrospective cohort analysis of all Candida 
BSI infections at our institution over a 13-year period. The pur-
pose of this study was to identify pertinent clinical comorbidi-
ties that could accurately predict CK BSI as well as to assess the 




We collected data from patients admitted to Barnes Jewish 
Hospital between January 2002 and January 2015, a 1315-bed 
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tertiary care hospital in St. Louis, Missouri. The study was 
approved by the Washington University in St. Louis Institutional 
Review Board with a waiver of consent.
Cohort Construction
Patients ≥18 years old who were hospitalized and had at least 
1 blood culture positive for Candida were eligible for study 
inclusion. Subsequent Candida BSI episodes in the same 
patient within 90 days were excluded. Through a combination 
of automated chart extraction and medical chart review by the 
authors, we collected Candida species and a series of patient 
characteristics (Table  1; Supplementary Tables 1 and 2). The 
most extreme vital signs (highest temperature, respiratory 
rate, and heart rate; lowest blood pressure) measured within 24 
hours preceding BSI were collected. Comorbidities were deter-
mined via ICD-9 codes (Supplementary Table 1) and included 
all Elixhauser comorbidities as they have been shown to be 
good predictors of death in acute illness [14]. We categorized 
Table 1. Comparison of Characteristics Between Patients With Candida krusei Bloodstream Infections and Those With Non-CK Bloodstream Infections
Characteristica CK (n = 59) Non-CK (n = 1814) P Valueb Total (n = 1873)
Demographics
 Age, median (IQR), y 57 (21) 59 (24) .5210 59 (24)
 Female sex 25 (42.4) 869 (47.9) .4024 894 (47.7)
 Race .0175
  White 43 (72.9) 1134 (62.5) 1177 (62.8)
  African American 10 (17.0) 588 (32.4) 598 (31.9)
  Other 6 (10.2) 92 (5.1) 98 (5.2)
Malignancy
 Leukemia 33 (55.9) 199 (11.0) <.0001 232 (12.4)
 Lymphoma 8 (13.6) 84 (4.6) .0070 92 (4.9)
 Hematologic 42 (71.2) 304 (16.8) <.0001 346 (18.5)
 Gastric 2 (3.4) 20 (1.1) .1509 22 (1.2)
Other potential predisposing factors
 Bone marrow transplant 9 (15.3) 27 (1.5) <.0001 36 (1.9)
 Cancer chemotherapy 12 (20.3) 99 (5.5) .0001 111 (5.9)
 Neutropenia 17 (28.8) 120 (6.6) <.0001 137 (7.3)
Laboratory values
 Absolute neutrophils count, median (IQR) 2.0 (11.2) 5.8 (6.2) .0092 5.7 (6.4)
 Neutropenia (ANC < 500) 23 (41.8) 150 (8.6) <.0001 173 (9.6)
 Platelets, median (IQR) 8 (78.5) 148 (175) <.0001 143 (178)
 Dichotomized creatinine (reference: ≤1) 21 (38.2) 883 (50.3) .0771 904 (49.9)
Medications ordered within 90 days prior to Candida BSI
 Azole 17 (28.8) 138 (7.6) <.0001 155 (8.3)
  Fluconazole 14 (23.7) 123 (6.8) <.0001 137 (7.3)
  Voriconazole 3 (5.1) 10 (0.6) .0068 13 (0.7)
  Clotrimazole 1 (1.7) 13 (0.7) .3622 14 (0.8)
  Itraconazole 0 (0) 4 (0.2) 1.0000 4 (0.2)
  Ketoconazole 0 (0) 1 (0.1) 1.0000 1 (0.05)
 Monoclonal antibodies 8 (13.6) 16 (0.9) <.0001 24 (1.3)
  Antilymphocyte 5 (8.5) 10 (0.6) <.0001 15 (0.8)
  Antimyeloid 1 (1.7) 2 (0.1) .0916 3 (0.2)
  Anti-TNF 3 (5.1) 4 (0.2) .0010 7 (0.4)
 Corticosteroids 36 (61.0) 493 (27.2) <.0001 529 (28.2)
 Antiherpes antivirals 31 (52.5) 240 (13.2) <.0001 271 (14.5)
 Antimetabolites 23 (39.0) 157 (8.7) <.0001 180 (9.6)
 Calcineurin inhibitors 14 (23.7) 76 (4.2) <.0001 90 (4.8)
 Cytotoxic agents 6 (10.2) 36 (2.0) .0016 42 (2.2)
 Mitotic inhibitors 7 (11.9) 40 (2.2) .0005 47 (2.5)
 mTOR inhibitors 3 (5.1) 14 (0.8) .0147 17 (0.9)
Descriptive statistics for additional variables are presented in Supplementary Table 2. 
Abbreviations: BMI, body mass index; CK, Candida krusei; IQR, interquartile range; mTOR, mechanistic target of rapamycin; TNF, tumor necrosis factor; TPN, total parenteral nutrition.
aUnless otherwise specified, characteristics are dichotomized and reported as absolute frequency (percent).
bP values for continuous variables were based on Mann-Whitney U statistical tests, while categorical variable P values were obtained from either chi-square or Fisher exact tests, as 
appropriate.
cThe most extreme vital signs (highest temperature, respiratory rate, and heart rate; lowest blood pressure) measured within 24 hours preceding BSI were collected.
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continuous variables that did not follow a linear distribution, 
and when significantly different, odds ratios were noted for dif-
ferent levels of the variable in univariate analyses.
Outcomes
For logistic regression, the outcome was defined as CK BSI vs 
non-CK BSI. For survival analysis, we assessed 90-day all-cause 
mortality. Dates of death were extracted from the hospital con-
sortium’s Medical Informatics database and supplemented 
with information from the Social Security Death Index (SSDI). 
Patients with a positive Candida blood culture and without con-
firmed death who were not observed in our institution after the 
90-day postdiagnosis period were censored at the date of last visit.
Statistical Analysis
Statistical analysis was performed using SAS v9.4 Software (SAS 
Institute Inc., Cary, NC), and all tests were 2-tailed. Survival 
graphs were created using SPSS V23 (IBM, Armonk, NY). For 
descriptive statistics, we used chi-square or Fisher exact tests for 
categorical variables and Mann-Whitney U tests for continuous 
variables, as the variables were not normally distributed.
We performed univariate logistic regression to evaluate the 
association of predisposing factors, comorbidities, medication 
use, and laboratory values with the development of CK BSI. We 
performed univariable Cox proportional hazards analysis to 
evaluate the association of these same factors with 90-day mor-
tality. Variables with P < .20 were evaluated in the multivariable 
models.
We developed the multivariable models in a parsimonious 
manner, adding candidate variables sequentially and retaining 
them in the model if they were found to be significant (P < .05). 
After all relevant variables were included, those that were no 
longer found to be significant were sequentially removed from 
the model. We generated a C-statistic and receiver operating 
characteristic (ROC) curve using the final set of predictor var-
iables. The Cox proportional hazards model was constructed 
in a similar manner, with the exception that the initial model 
contained Candida species as the dependent variable, dichoto-
mized as CK vs non-CK, and all other variables were tested in 
the model as confounders (changed the CK parameter estimate 
by at least 15% in either direction).
RESULTS
Demographics
A total of 1913 hospitalized patients were diagnosed with 
Candida BSI in the study period. Forty observations were dis-
carded due to duplication, incomplete data collection, and not 
fulfilling inclusion/exclusion criteria, resulting in 1873 obser-
vations analyzed. Of these, 59 were due to CK. Absolute and 
relative frequency of CK BSI did not significantly change over 
time. CK constituted between 1.8% and 5.4% of total Candida 
BSI events between 2002 and 2015, and there has been no con-
sistent trend over time (Supplementary Figure 1).
Significant and relevant descriptive comparison between 
CK and non-CK BSI can be found in Table 1, and the others in 
Supplementary Table 2. Age and sex distributions were similar 
between the 2 groups, while CK BSI was diagnosed more often 
in white patients (72.9% vs 62.5%). Many comorbidities were 
present at similar rates between the groups. However, patients 
with CK BSI were significantly more likely to have hematologic 
cancer (71.2% vs 16.8%), and were also significantly more likely 
to have a history of bone marrow transplant (15.3% vs 1.5%) 
and to have received chemotherapy (20.3% vs 5.5%). CK BSI 
patients were more likely to have received certain medications 
within the 90 days leading up to the incident infection, includ-
ing azole antifungals, echinocandins, and corticosteroids.
Clinical Predictive Model
In univariate logistic regression analyses, 65 variables were 
found to be associated with the development of CK BSI 
(Supplementary Table 3).
Six variables were included in the final multivariable logistic 
regression model: hematologic malignancy (odds ratio [OR], 
10.7; 95% confidence interval [CI], 5.1–22.4), gastric malig-
nancy (OR, 14.7; 95% CI, 3.0–72.8), neutropenia (OR, 2.1; 95% 
CI, 1.1–4.1), prior azole use (OR, 2.4; 95% CI, 1.2–4.7), prior 
monoclonal antibody use (OR, 5.4; 95% CI, 2.0–14.9), and 
β-lactam/β-lactamase inhibitor use (OR, 2.4; 95% CI, 1.3–4.7) 
within 90 days prior to Candida BSI (Table 2). Prior monoclo-
nal antibody use included all patients receiving antilymphocyte 
antibodies, antimyeloid antibodies, and/or anti–tumor necrosis 
factor antibodies. The C-statistic for this model was 0.86 (95% 
CI, 0.81–0.91) (Figure 1).
Mortality
Mortality was increased in CK BSI patients compared with 
non-CK BSI patients in univariable analysis (64.4% vs 
41.4%; hazard ratio [HR], 1.8; 95% CI, 1.3–2.4) (Figure  2, 
Supplementary Table 4).
Five variables were included in the final multivariable Cox 
model: neutropenia (HR, 2.0; 95% CI, 1.6–2.5), lymphoma (HR, 
1.5; 95% CI, 1.1–2.0), prior glucocorticoid use (HR, 1.4; 95% 
CI, 1.2–1.7), chronic liver disease (HR, 2.0; 95% CI, 1.6–2.5), 
and creatinine >1 mg/dL (HR, 2.1; 95% CI, 1.8–2.5) (Table 3). 
With the addition of these covariates, the association between 
CK BSI and mortality was no longer significant (HR, 1.3; 95% 
CI, 0.9–1.8) (Figure 2).
DISCUSSION
CK is associated with high mortality and resistance to antifun-
gal agents; therefore, understanding the underlying risk factors 
for development of the infection and mortality in this popu-
lation is of high clinical importance. Hematologic malignancy, 
gastric malignancy, neutropenia, prior azole use, prior mono-
clonal antibody use, and prior β-lactam/β-lactamase inhibitor 
use are independent risk factors for the development of CK BSI 
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in our multivariable logistic regression model. The discrimi-
nating performance of this model is higher than some of the 
most commonly used clinical predictive models [15]. Although 
patients with CK BSI appear to have a higher mortality rate than 
non-CK BSI patients, this association is no longer significant 
when taking into account confounders, specifically neutrope-
nia, lymphoma, prior glucocorticoid use, chronic liver disease, 
and elevated creatinine.
While CK is 1 of 5 Candida species composing >90% of all 
isolates, it is also the least common of these [1]. We found CK 
to constitute 3.2% of all Candida BSI at our institution, which is 
consistent with a previously published range of 0.9%–10% [7, 12, 
16–18]. A systematic review of Candida BSI prevalence world-
wide found that CK consistently made up 1%–4% of infections 
regardless of geographic location, with the exception of 2 studies 
conducted in Finland and France with proportions of 8.5% and 
10.6%, respectively [19]. There is no consensus as to whether 
the incidence of CK is truly increasing, as results from different 
studies are conflicting. However, the majority of studies suggest 
a stable epidemiology, consistent with our findings [4, 19, 20]. It 
is possible that the studies that show a rise in CK are either outli-
ers or represent localized changes in epidemiology.
Several of the risk factors associated with CK BSI in our cohort 
have been corroborated in previous studies. Observationally, 
CK is disproportionately isolated in hematology units [7, 21] 
and neutropenia and hematologic malignancy are consistently 
associated with CK BSI across multiple studies [8, 11, 12, 16]. 
A prospective cohort of patients diagnosed with Candida BSI 
between 2004 and 2008 found that CK BSI was more com-
mon in the setting of prior use of antifungal agents, hemato-
logic malignancy, stem cell transplantation, neutropenia, and 
corticosteroid therapy, although the authors did not adjust for 
multiple variables [22]. In our analysis, bone marrow transplan-
tation and corticosteroid therapy were significant in univariate 
analyses but did not meet criteria for inclusion in multivariable 
analyses, appearing to have no increase in predictability in add-
ition to hematologic malignancy and neutropenia.
We found a specific predilection for CK BSI in patients with 
prior azole use, which has biological plausibility given the known 
intrinsic resistance to fluconazole (and other azoles, to a lesser 
extent) in this species [20, 23, 24]. Various studies have suggested 
increased risk in the setting of fluconazole exposure, with 1 study 
demonstrating dose dependency [25–28]. Although 1 case-con-














Figure 1. Receiver operating characteristic curve for the multiple logistic regres-
sion predicting Candida krusei bloodstream infection. The C-statistic is 0.8618 (95% 
confidence interval, 0.8094–0.9141). Predictor variables are hematologic malig-
nancy, gastric malignancy, neutropenia, and prior azole, monoclonal antibody, and 
β-lactam/β-lactamase inhibitor use within 90 days prior to the Candida infection.
Table 2. Clinical Predictive Calculator for Candida krusei vs Other Candida Bloodstream Infection
Variable Parameter Estimate Odds Ratio (95% CI) P Value
Intercept –5.1811 n/a n
Hematologic malignancya 2.3664 10.659 (5.067–22.422) <.0001
Gastric malignancy 2.6862 14.676 (2.957–72.849) .0010
Neutropeniab 0.7471 2.111 (1.091–4.086) .0266
Prior azole usec 0.8623 2.369 (1.204–4.658) .0125
Prior monoclonal antibody usec 1.6884 5.411 (1.964–14.910) .0011
Prior β-lactam/β-lactamase
inhibitor usec
0.8880 2.430 (1.251–4.722) .0088
P CK
e X X X X
( )=
+ - - + + + +
1
1 5 1811 2 3664 1 2 6862 2 0 7471 3 0 8623( . . * . * . * . * 4 1 6884 5 0 888 6+ +. * . * )X X ,
where X1 = hematologic malignancy, X2 = gastric malignancy, X3 = neutropenia, X4 = prior azole use, X5 = prior monoclonal antibody use, and X6 = prior β-lactam/β-lactamase inhibitor use.
Abbreviations: CI, confidence interval; CK, Candida krusei.
aIncludes any history or diagnosis of leukemia, lymphoma, or multiple myeloma.
bDefined as absolute neutrophil count <500/mm3.
cMedication was ordered within 90 days prior to Candida infection.
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BSI, this study included only 4 patients with CK [29]. Given that 
azole prophylaxis is often given in the setting of severe immu-
nosuppressive disease (eg, hematologic malignancy and trans-
plantation), some authors have suggested association rather than 
a true biological causation [30]. However, in 1 study limited to 
adult patients with leukemia or status post–bone marrow trans-
plant, fluconazole prophylaxis was still associated with CK BSI 
[31]. The authors posited that emergence of a relatively low-viru-
lence organism such as CK was aided by the suppression of other 
more virulent Candida species susceptible to fluconazole.
In addition to azoles, β-lactam/β-lactamase inhibitors and 
monoclonal antibodies were associated with CK BSI. Although 
antibiotics have been infrequently studied in this setting, 1 
prior case-control study found that β-lactams, vancomycin, and 
aminoglycosides were associated with CK BSI, with the strong-
est association seen for antibiotics with anaerobic activity [10]. 
Presumably, antibiotics may predispose individuals to Candida 
BSI through alteration of the microbiome at sites of inoculation. 
However, the significance of the interaction between certain 
antibiotic classes and Candida species is unclear. Similarly, while 
the ability of monoclonal antibodies to significantly affect immu-
nologic mechanisms suggests a pathway by which low-virulence 
organisms such as CK gain a foothold in an otherwise overly 
hostile environment, this area requires further investigation.
In our multivariable analysis, gastric malignancy was the 
only solid tumor significantly associated with the development 
of CK BSI. Gastrointestinal (GI) inoculation as a source of CK 
BSI may explain this association, as disruption of the GI barrier 
by tumor cells and associated inflammation could potentially 
lead to higher inoculation rates, although this mechanism is 
theoretical and may not be specific to CK [32, 33].
CK BSI was associated with higher mortality as compared 
with non-CK BSI in the univariate analysis (64.4% vs 41.4%; 
HR, 1.8; 95% CI, 1.3–2.4). The mortality in our study is gener-
ally consistent with that cited by other authors [34–36]. While 
mortality with CK BSI tends to be higher than non-CKI BSI in 
the majority of studies, this difference is often not statistically 
significant, likely related to low power in the setting of infre-
quent CK infection [8, 12, 34]. In 1 study with comparable sam-
ple sizes and species distributions, CK was found to have the 
highest 90-day mortality rate (52.9%) of all species when com-
paring them individually [22]. Another study found CK BSI to 
be associated with a similarly poor 90-day mortality of 46.4%, 
compared with 38.7% for all Candida BSI [12].
Our multivariable survival analysis suggests that the higher 
crude mortality seen with CK BSI reflects the underlying sever-
ity of illness in these patients rather than pathogenic virulence 
of the organism [32]. Indeed, in vitro and in vivo virulence 
testing has demonstrated that CK is a relatively low-virulence 
organism [18, 33], although several unique intrinsic mecha-
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Figure 2. Univariable (A) and multivariable (B) proportional hazards model stratified by Candida krusei bloodstream infection (dashed) vs other Candida bloodstream infec-
tion (solid). Time was measured from the date of first positive culture. Patients were censored at either date of death or date last seen, as reflected in the medical chart and 
the Social Security Death Index. The multivariable model is adjusted for lymphoma, neutropenia, glucocorticoid use, chronic liver disease, and elevated creatinine.
Table  3. Multivariable Proportional Hazards (Cox) Model Predicting 
Mortality in Patients With Candida Bloodstream Infection
Variable Hazard Ratio (95% CI) P Value
Candida kruseia 1.297 (0.909–1.849) .1514
Neutropeniab 1.984 (1.593–2.472) <.0001
Lymphoma 1.488 (1.124–1.970) .0055
Prior glucocorticoid usec 1.425 (1.218–1.667) <.0001
Chronic liver disease 2.005 (1.593–2.525) <.0001
Elevated creatinined 2.125 (1.835–2.461) <.0001
Abbreviation: CI, confidence interval.
aModels Candida krusei in comparison with all other Candida species.
bDefined as absolute neutrophil count <500/mm3.
cMedication was ordered within 90 days prior to Candida infection.
dDefined as >1 mg/dl.
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oxidative stress [37, 38]. While hematologic malignancy pre-
dicted CK BSI, only lymphoma was an independent predictor 
of mortality. One possible explanation for this discrepancy may 
be the convergence of leukemia and neutropenia as they relate 
to mortality, whereas other sources of immune dysfunction in 
hematologic malignancy may contribute to the development of 
CK BSI. Regardless of their role in the initial CK BSI, liver dis-
ease, kidney dysfunction, and immunosuppression appear to be 
strong mediators of CK BSI–associated mortality.
This study is limited by retrospective data collection. While the 
database was built to maximize comprehensiveness, ICD-9 codes 
may not always reflect true diagnoses, leading to misclassification 
bias. Additionally, we were unable to identify changes in diagnostic 
accuracy and management over time that may have contributed to 
variations in mortality, although mortality in this cohort did not 
appear to change significantly over time. Despite a large overall 
sample size, our analyses were based on comparison with only 59 
patients with CK BSI due to the relative infrequency of infection 
by this species. This limited our statistical power, although this is 
the largest study to look at patients with CK BSI. Finally, this study 
was conducted at a single tertiary care academic center and thus 
may not be generalizable to other populations.
In conclusion, we found that a collection of patient comor-
bidities could both predict the development of CK BSI and 
explain the increased mortality seen in these patients.
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